Viking Therapeutics, Inc. (VKTX) Advances Obesity Drug Development and Expands Metabolic Disease Pipeline

Data published successful the peer-reviewed diary Obesity amusement that the cause achieved a value nonaccomplishment of 14.7% from baseline aft 13 weeks of treatment, with nary plateau observed. The objective proceedings besides met some superior and secondary endpoints. Following the affirmative Phase 2 trials, Viking is evaluating VK2735 successful the Phase 3 VANQUISH-1 trial. It has already enrolled astir 4,650 patients.

“The survey information served to item the committedness that VK2735 holds arsenic a perchance best-in-class dual GLP-1/GIP agonist and were cardinal to our designing of the ongoing VANQUISH Phase 3 program,” said Brian Lian, CEO of Viking Therapeutics.

The affirmative objective trials travel arsenic involvement successful value nonaccomplishment cause deals remains beardown successful the market. According to Viking Therapeutics CEO Brian Lian, cause makers are progressively seeking ways to pat into the imaginable $150 cardinal market.

Viking Therapeutics, Inc. (NASDAQ:VKTX) is simply a clinical-stage biopharma institution processing drugs for metabolic and endocrine diseases, notably obesity, fatty liver (MASH), and uncommon conditions.

While we admit the imaginable of VKTX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: Top 10 Materials Stocks to Buy According to Analysts and 10 Best Organic Food and Farming Stocks to Buy Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.